DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Oportuzumab monatox
Oportuzumab monatox
Horizon Scanning Status Report June 2019
2017 Immuno-Oncology Medicines in Development
Tables-Of-Phase-3-Mabs.Pdf
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
(INN) for Biological and Biotechnological Substances
Immunotoxins: Targeted Toxin Delivery for Cancer Therapy
Prescrire's Response
Antibody-Drug Conjugates in Bladder Cancer
INN Working Document 05.179 Update 2011
Debouganin Diabody Fusion Protein Overcomes Drug Resistance to Adcs Comprised of Anti-Microtubule Agents
Immunotoxin Screening System: a Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities
November 2019
Horizon Scanning Status Report December 2020
Ulipristal Acetate
(INN) for Biological and Biotechnological Substances
OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
PDF of Antibody News
Top View
Specialty Pipeline: March 2021
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
2020 Medicines in Development ꟷ Cancer
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
A View Into Upcoming Specialty & Traditional Drugs
CHMP Agenda of the 25-29 January 2021 Meeting
PCORI Horizon Scanning Status Report. March 2019
Nadofaragene Firadenovec and Oportuzumab Monatox for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer: Effectiveness and Value
Specialty Pipeline Monthly Update June 2021
Antibodies to Watch in a Pandemic
(INN) for Biological and Biotechnological Substances
Pipeline Report May 2021
The Chemistry Behind Adcs
New Therapeutic Targets in the Management of Urothelial Carcinoma of the Bladder
Antibodies to Watch in 2020
Novel Molecular Targets for the Therapy of Urothelial Cancer
IMGT/Mab-DB: the IMGT® Database for Therapeutic Monoclonal Antibodies
Recommended INN: List 62